Back to results

Massachusetts Institute of Technology

Learning from pre-pandemic data to design and test future-proof therapeutics

Abstract

dc:description.abstract

Effective pandemic preparedness relies on predicting immune-evasive viral mutations to enable early detection of variants of concern and design vaccines and therapeutics that are resilient to future viral evolution. However, current strategies for viral evolution prediction are not available early in a pandemic and have limited predictive power – experimental approaches require host polyclonal antibodies and existing computational methods draw heavily from current strain prevalence. In addition, vaccines and therapeutics have been designed with an eye towards past or circulating variants, not towards future evolution. To address these challenges, we developed EVEscape, a generalizable framework that integrates fitness predictions from a deep generative model of evolutionary sequences with biophysical and structural information. EVEscape quantifies the immune escape potential of viral strains at scale and is applicable before surveillance sequencing, experimental scans, or 3D structures of antibody complexes are available. We demonstrate that EVEscape, trained on sequences available prior to 2020, performs as accurately as high-throughput experimental scans at anticipating pandemic variation for SARS-CoV-2 and is generalizable to other viruses including Influenza A virus, HIV, and understudied viruses with pandemic potential such as Lassa and Nipah. We investigate both alignment-based and protein language models to explore the best model of mutation effects across pandemic-threat viral families. We demonstrate the utility of EVEscape in three critical applications: (1) Surveillance efforts flagging high escape SARS-CoV-2 variants from their first appearance (2) Design of panels of viral antigens that mimic future viral variants for early, proactive evaluation of the future protection of vaccines and therapeutic; and (3) Design of a pan-sarbecovirus nanoparticle-based vaccine capable of eliciting broad, long-lasting protection against sarbecoviruses, including future variants. This three-pronged approach represents a paradigm shift in pandemic preparedness, offering a novel strategy to preemptively address viral families with pandemic potential and significantly bolster global prevention efforts.

Degree

thesis:*
Name thesis:degree_name
Doctoral
Department dc:contributor.department
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Grantor dc:publisher
Massachusetts Institute of Technology
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Gurev, Sarah
Advisor dc:contributor.advisor
  • Marks, Debora

Rights

dc:rights
Statement dc:rights
  • In Copyright - Educational Use Permitted
  • Copyright retained by author(s)

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/1721.1/164504
OAI identifier oai:identifier
oai:dspace.mit.edu:1721.1/164504

Chain of custody

source
Harvested from
MIT
Base URL
dspace.mit.edu/oai/request
Last updated
2026-07-22
Source record
OAI-PMH GetRecord
related terms
citation

Gurev, Sarah. Learning from pre-pandemic data to design and test future-proof therapeutics. Massachusetts Institute of Technology, 2025. https://hdl.handle.net/1721.1/164504